ARDANA BOARD CHANGES

Edinburgh, UK, 28 June, 2007; Ardana, the company focused on improving human reproductive health, today announces the appointment of Dr Chris Moyses to its Board of Directors as a non-executive director and the retirement from the Board of Ian Kent after seven years’ service.  Both changes are with immediate effect.

Dr Moyses is a member of the Royal College of Physicians of London and is currently Chief Medical Officer and director of Argenta Discovery Limited and the non- executive chairman of Senexis Limited.  His previous positions include Research and Development Director of Pharmagene plc, Chief Medical Officer and director of Oxford GlycoSciences plc and Vice President of Clinical and Regulatory Affairs at Amylin Europe.

Dr Moyses will also become a member of Ardana’s Nominations and Corporate Governance Committee, Audit Committee and Remuneration Committee.

With reference to paragraphs 9.6.13 (1)–(6) of the FSA’s Listing Rules, there are no other disclosures required.

Ian Kent joined the Ardana Board as a founder non executive director and Chairman in 2000.  He relinquished the role of non executive Chairman in 2004.  Huw Jones replaces Ian as the Chairman of the Remuneration Committee.

Maureen Lindsay, CEO of Ardana, said:

“We are very grateful for the support and direction that Ian has given to Ardana since its inception and we wish him every success for the future.  We welcome Chris to Ardana.  He brings considerable pharmaceutical medical and regulatory knowledge and experience to our Board that will be invaluable to us as we expand our business and development product pipeline.”

For more information contact:

back to top